Company Overview and News


Add GSK
to your dashboard

Headline News

Why is Puma (PBYI) Stock Up More than 150% in a Year's Time?

2h zacks
Shares of Puma Biotechnology, Inc. (PBYI - Free Report) have significantly outperformed the industry in a year. The stock has skyrocketed 186.4% compared with the industry’s increase of 3.3% during the period. (52-0)

2018 Strategic Outlook: Will Fortune Favor The Bold In Biotech?

3h seekingalpha
Significant scientific and technological breakthroughs, combined with unabated M&A appetite and tax reform, provide fertile ground for biotech gains in 2018. (302-0)

Glaxo's Influenza Vaccine Gets FDA Nod for Label Expansion

2018-01-15 zacks
GlaxoSmithKline plc (GSK - Free Report) received approval from the FDA’s Center for Biologics Evaluation and Research for the label expansion of influenza vaccine — FluarixQuadrivalent. The vaccine has been approved for infants six months or older.  (59-0)

Your Daily Pharma Scoop: Lipocine's Gloomy Future, Puma Labeling Change, Concert's Mixed Day

2018-01-13 seekingalpha
Puma plans to modify labeling in its European marketing application for its breast cancer candidate neratinib. (254-4)

Analysis: Drugmakers see a pricing blueprint in an $850,000 gene therapy

2018-01-13 in.reuters
SAN FRANCISCO (Reuters) - Global drugmakers are looking to a tiny biotech’s $850,000 therapy for a rare type of blindness as a model for getting paid for highly expensive – and effective – new medicines. (45-0)

Drugmakers see a pricing blueprint in an $850,000 gene therapy

2018-01-12 reuters
SAN FRANCISCO (Reuters) - Global drugmakers are looking to a tiny biotech’s $850,000 therapy for a rare type of blindness as a model for getting paid for highly expensive – and effective – new medicines. (45-0)

Drugmakers see a pricing blueprint in an US$850,000 gene therapy - Channel NewsAsia

2018-01-12 channelnewsasia
SAN FRANCISCO: Global drugmakers are looking to a tiny biotech's US$850,000 therapy for a rare type of blindness as a model for getting paid for highly expensive – and effective – new medicines. (45-0)

Pharma Stock Roundup: Novo Nordisk Reveals Bid to Acquire Ablynx, Pfizer & Others at Healthcare Conference

2018-01-12 zacks
Focus this week was on the 36th annual JPMorgan healthcare conference where several biotech and pharma companies provided a preliminary look at their results for 2017 and also provided pipeline updates as well as their outlooks for 2018. Recap of the Week’s Most Important Stories Key Takeaways from JPMorgan Healthcare Conference: Several pharma companies were present at the 36th annual JPMorgan healthcare conference, the largest and most informative healthcare investment symposium in the industry. (18-0)

AstraZeneca's Asthma Drug Benralizumab Gets Approval in EU

2018-01-11 zacks
AstraZeneca, plc (AZN - Free Report) announced that the European Commission (“EC”) has granted approval to its asthma disease candidate, benralizumab. It is approved as an add-on maintenance treatment for severe eosinophilic asthma in adult patients. It will be marketed by the trade name of Fasenra. (344-0)

EU Launches $1.2 Billion Supercomputing Plan, Without U.K. - Bloomberg

2018-01-11 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (5-0)

Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar

2018-01-10 zacks
Novartis AG (NVS - Free Report) initiated a head-to-head trial, SURPASS, on psoriasis drug, Cosentyx. The drug will be compared to its proposed biosimilar for the treatment of ankylosing spondylitis (AS). (145-0)

Emergent Down on '18 View, Posts Preliminary '17 Results

2018-01-09 zacks
Emergent BioSolutions Inc. (EBS - Free Report) provided preliminary results for 2017 and its guidance for 2018. While the results exceeded management’s guidance issued in November 2017, the company’s shares fell almost 3% as the 2018 outlook lagged market expectations. (34-0)

Zymeworks - Protein Proficiency At A Discount

2018-01-09 seekingalpha
The company's internal candidates are highly promising, reinforcing the value proposition of the company's software platform. (115-1)

Glaxo Shifts to Boost Growth With Astra Threatening to Pass - Bloomberg

2018-01-09 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (68-0)

Your Daily Pharma Scoop: Ablynx Takeover Bid, Celgene Acquires Impact Biomedicines, Axovant Flops Again

2018-01-09 seekingalpha
Today we will discuss the hostile takeover bid from Novo Nordisk (NVO) for clinical-stage Belgian biotech company Ablynx (OTCPK:ABLYF). (411-4)